Microba Life Sciences Ltd (MAP)

Currency in AUD
0.05
0.00(0.00%)
Closed·
Trading near 52-week Low
MAP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.040.05
52 wk Range
0.040.10
Key Statistics
Bid/Ask
0.04 / 0.05
Prev. Close
0.05
Open
0.05
Day's Range
0.04-0.05
52 wk Range
0.04-0.1
Volume
407.07K
Average Volume (3m)
980.92K
1-Year Change
-47.3684%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MAP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.08
Upside
+68.22%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.08
(+68.22% Upside)

Microba Life Sciences Ltd Earnings Call Summary for Q4/2026

  • Microba reported FY26 core testing revenue up 92% and volume up 78%, with Q4 volume rising 54% as enterprise adoption accelerated in Australia and U.K.
  • Company signed 43 enterprise accounts in Australia with pipeline of 175 targets representing 80,000+ annual test potential; ordering clinicians rose 22% domestically.
  • Premium GI Navigator diagnostic product on track for September 2026 launch; management targeting full-group cash flow breakeven on run-rate basis by calendar 2027.
  • Shares traded flat at $0.04, near 52-week low, as market awaits proof growth converts to profitability; recent AUD 5M capital raise to fund breakeven push.
  • Therapeutics partnering campaign underway for MAP315 ulcerative colitis asset; cost reductions planned outside core growth functions to preserve sales momentum.
Last Updated: 16/07/2026, 03:58 pm
Read Full Transcript

Earnings

Latest Release
29/04/2026
EPS / Forecast
-- / --
Revenue / Forecast
3.36M / --
EPS Revisions
Last 90 days

MAP Income Statement

Compare MAP to Peers and Sector

Metrics to compare
MAP
Peers
Sector
Relationship
P/E Ratio
−1.4x16.5x−0.4x
PEG Ratio
0.080.020.00
Price/Book
0.9x1.4x2.6x
Price / LTM Sales
1.8x1.0x3.0x
Upside (Analyst Target)
68.2%30.6%57.2%
Fair Value Upside
Unlock22.9%9.6%Unlock

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
71.40M11.72%3.21M
Other Institutional Investors
356.56M58.55%16.05M
Public Companies & Retail Investors
181.01M29.72%8.15M
Total
608.96M100.00%27.4M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Sonic Healthcare Limited25.42%154,823,3836,967
Perennial Value Management Limited15.08%91,810,1844,131

FAQ

What Is the Microba Life Sciences (MAP) Stock Price Today?

The Microba Life Sciences stock price today is 0.05 AUD.

What Stock Exchange Does Microba Life Sciences Trade On?

Microba Life Sciences is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Microba Life Sciences?

The stock symbol for Microba Life Sciences is "MAP."

What Is the Microba Life Sciences Market Cap?

As of today, Microba Life Sciences market cap is 27.40M AUD.

What Is Microba Life Sciences's Earnings Per Share (TTM)?

The Microba Life Sciences EPS (TTM) is -0.04.

When Is the Next Microba Life Sciences Earnings Date?

Microba Life Sciences will release its next earnings report on 01/09/2026.

From a Technical Analysis Perspective, Is MAP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Microba Life Sciences Stock Split?

Microba Life Sciences has split 0 times.

What is the current trading status of Microba Life Sciences (MAP)?

As of 25/07/2026, Microba Life Sciences (MAP) is trading at a price of 0.05 AUD, with a previous close of 0.05 AUD. The stock has fluctuated within a day range of 0.04 AUD to 0.05 AUD, while its 52-week range spans from 0.04 AUD to 0.10 AUD.

What Is Microba Life Sciences (MAP) Price Target According to Analysts?

The average 12-month price target for Microba Life Sciences is 0.08 AUD, with a high estimate of 0.11822 AUD and a low estimate of 0.05 AUD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +68.22% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.